FIS Names Stephanie Ferris as President

Key facts:

  • Stephanie Ferris joined FIS in 2019 through the company's acquisition of Worldpay where she served as Chief Financial Officer.
  • A 27-year financial services veteran, Ferris most recently served as Chief Administrative Officer of FIS.

Financial technology leader FIS ® (NYSE: FIS) today announced the promotion of Stephanie Ferris to company President effective Feb. 8.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220208006106/en/

FIS announced the promotion of Stephanie Ferris to company President, effective Feb. 8. Ferris is a 27-year financial services veteran. (Photo: Business Wire)

FIS announced the promotion of Stephanie Ferris to company President, effective Feb. 8. Ferris is a 27-year financial services veteran. (Photo: Business Wire)

Ferris most recently served as FIS Chief Administrative Officer (CAO), having joined the company through its 2019 acquisition of Worldpay where she served as Chief Financial Officer.

After joining FIS, she assumed the role of Chief Operating Officer where she led the integration of Worldpay into FIS, surpassing both revenue and cost synergy commitments. Ferris' most recent role as CAO saw her lead a global team responsible for the company's enterprise strategy, finance, mergers and acquisitions, legal, marketing and communications, risk, information security and compliance functions.

"Stephanie is a tremendously talented leader and we're fortunate to leverage her extensive industry and financial insights to help accelerate our growth and shape the future of FIS," stated FIS Chairman and CEO Gary Norcross. "Her bold, experienced leadership will ensure that FIS continues to set the pace for how the world pays, banks and invests."

About FIS

FIS is a leading provider of technology solutions for merchants, banks and capital markets firms globally. Our employees are dedicated to advancing the way the world pays, banks and invests by applying our scale, deep expertise and data-driven insights. We help our clients use technology in innovative ways to solve business-critical challenges and deliver superior experiences for their customers. Headquartered in Jacksonville, Florida, FIS ranks #241 on the 2021 Fortune 500 and is a member of Standard & Poor's 500® Index. To learn more, visit www.fisglobal.com . Follow FIS on Facebook , LinkedIn and Twitter ( @FISGlobal ).

Kim Snider, 904.438.6278
Senior Vice President
FIS Global Marketing and Communications
kim.snider@fisglobal.com

News Provided by Business Wire via QuoteMedia

FIS
The Conversation (0)
Brunswick Continues to Intersect Lithium Mineralization on Globex's Lac Escale Royalty Property

Brunswick Continues to Intersect Lithium Mineralization on Globex's Lac Escale Royalty Property

GLOBEX MINING ENTERPRISES INC. (GMX Toronto Stock Exchange, G1MN Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf Stock Exch anges and GLBXF OTCQX International in the US) is pleased to report that Brunswick Exploration Inc. (BRW-TSXV, BRWXF-OTCQB) in a press release today, announced additional wide intersections of lithium mineralization on Globex's Lac Escale royalty claims, a part of Brunswick's Mirage property.

Intersections include 36 meters grading 1.51% Li 2 O in Hole MR-24-102 and 1.32% Li 2 O over 28 metres in Hole MR-24-101. A total of 24 drill holes were completed in the winter drill program. Please access Brunswick's press release of today's date for further details.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies (TSXV:ZCT)

Zero Candida Announces Plans to Complete Preclinical Studies for FDA Submission by Q3 2025

Zero Candida Technologies, Inc. (TSXV: ZCT), (FSE: 9L2) (the "Company" or "ZCT"), an Israeli FemTech medical device company focused on revolutionizing women's health, announces plans to complete preclinical studies for FDA submission by Q3 2025. In accordance with FDA requirements, the company is preparing to conduct a full preclinical study of its final human-use device in up to 24 additional sheep.

The company has successfully completed a two sheep protocol pilot trial in November 2023, and is now preparing to expand the study. The ZC-1-A device was confirmed as 100% safe for use, with findings concluded from the Shamir Medical Center.

Keep reading...Show less

Latest Press Releases

Related News

×